EP Patent

EP1588704A1 — Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders

Assigned to Newron Pharmaceuticals SpA · Expires 2005-10-26 · 21y expired

What this patent protects

Methods of using certain α-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the syntoms of RLS and addictive disorders substantially without side effects.

USPTO Abstract

Methods of using certain α-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the syntoms of RLS and addictive disorders substantially without side effects.

Drugs covered by this patent

Patent Metadata

Patent number
EP1588704A1
Jurisdiction
EP
Classification
Expires
2005-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Newron Pharmaceuticals SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.